Efficacy of treatment with montelukast, fluticasone propionate and budesonide liquid suspension for the prevention of recurrent asthma paroxysms in children with wheezing disorders

Ding,Bo; Lu,Yanming; Li,Yaqin; Zhou,Wenjing; Qin,Feng

doi:10.3892/etm.2019.7894

Efficacy of treatment with montelukast, fluticasone propionate and budesonide liquid suspension for the prevention of recurrent asthma paroxysms in children with wheezing disorders

Authors:
- Bo Ding
- Yanming Lu
- Yaqin Li
- Wenjing Zhou
- Feng Qin
View Affiliations

Affiliations: Department of Pediatrics, the Southern Division of Renji Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai 201112, P.R. China
Published online on: August 14, 2019 https://doi.org/10.3892/etm.2019.7894
Pages: 3090-3094
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abstract. One‑third of the children who suffer from first‑time wheezing are estimated to experience recurrences; however, no standard therapeutic strategy with which to prevent these recurrences currently exists. A few studies have compared the three drugs commonly used for the treatment of persistent asthma in children to identify the most effective one for preventing recurrent wheezing. In this study, in an aim to determine the most effective of these drugs, we recruited patients <5 years of age with recurrent wheezing at our hospital, and assigned them randomly to either the oral montelukast [leukotriene receptor antagonist (LTRA)], the inhaled fluticasone propionate (FP), or the inhaled budesonide suspension (BUD) groups for 12‑week treatments. We then determined the treatment efficacy (symptomatic improvement) by recording the number of wheezing episodes and emergency visits, the daily treatment cost, the mean accumulated down time and the patient compliance; we then compared the results among the groups. All treatments were found to be equally effective. The daily cost of inhaled FP was lower than that of oral LTRA and inhaled BUD (P<0.00001). The difference in the mean accumulated down time between these groups was not significant (P=0.132). The adherence (patient compliance) to LTRA was significantly higher than the adherence to inhaled corticosteroids (ICS) (P<0.017). On the whole, the findings of this study indicated that all three treatments prevented recurrent wheezing in our pediatric population. FP was found to be more convenient, to require fewer doses, and that it could be easily adjusted. Patient adherence/compliance to treatment was significantly better with LTRA than with ICS.

View Figures

View References

1	Brand PLP, Caudri D, Eber E, Gaillard EA, Garcia-Marcos L, Hedlin G, Henderson J, Kuehni CE, Merkus PJ, Pedersen S, et al: Classification and pharmacological treatment of preschool wheezing: Changes since 2008. Eur Respir J. 43:1172–1177. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ducharme FM, Dell SD, Radhakrishnan D, Grad RM, Watson WT, Yang CL and Zelman M: Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper. Can Respir J. 22:135–143. 2015. View Article : Google Scholar : PubMed/NCBI
3	Beigelman A and Bacharier LB: Infection-induced wheezing in young children. J Allergy Clin Immunol. 133:603–604. 2014. View Article : Google Scholar : PubMed/NCBI
4	Hu YM, Jiang ZF, Shen K and Shen Y: Zhu Fu-Tang Textbook of Paediatrics8th. People's Medical Publishing; Beijing: 2012
5	El-Gamal YM and El-Sayed SS: Wheezing in infancy. World Allergy Organ J. 4:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ferrante G and La Grutta S: The Burden of Pediatric Asthma. Front Pediatr. 6:1862018. View Article : Google Scholar : PubMed/NCBI
7	Rodríguez-Martínez CE, Sossa-Briceño MP and Castro-Rodriguez JA: Factors predicting persistence of early wheezing through childhood and adolescence: A systematic review of the literature. J Asthma Allergy. 10:83–98. 2017. View Article : Google Scholar : PubMed/NCBI
8	Rossi GA and Colin AA: Infantile respiratory syncytial virus and human rhinovirus infections: Respective role in inception and persistence of wheezing. Eur Respir J. 45:774–789. 2015. View Article : Google Scholar : PubMed/NCBI
9	Wu YF, Su MW, Chiang BL, Yang YH, Tsai CH and Lee YL: A simple prediction tool for inhaled corticosteroid response in asthmatic children. BMC Pulm Med. 17:1762017. View Article : Google Scholar : PubMed/NCBI
10	Ye Q, He XO and D'Urzo A: A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma. Pulm Ther. 3:1–18. 2017. View Article : Google Scholar
11	Turunen R, Koistinen A, Vuorinen T, Arku B, Söderlund-Venermo M, Ruuskanen O and Jartti T: The first wheezing episode: Respiratory virus etiology, atopic characteristics, and illness severity. Pediatr Allergy Immunol. 25:796–803. 2014. View Article : Google Scholar : PubMed/NCBI
12	Piedimonte G, Renzetti G, Auais A, Di Marco A, Tripodi S, Colistro F, Villani A, Di Ciommo V and Cutrera R: Leukotriene synthesis during respiratory syncytial virus bronchiolitis: Influence of age and atopy. Pediatr Pulmonol. 40:285–291. 2005. View Article : Google Scholar : PubMed/NCBI
13	Wang X, Zhou J, Zhao X and Yi X: Montelukast Treatment of Acute Asthma Exacerbations in Children Aged 2 to 5 Years: A Randomized, Double-Blind, Placebo-Controlled Trial. Pediatr Emerg Care. 34:160–164. 2018. View Article : Google Scholar : PubMed/NCBI
14	Hosoki K, Kainuma K, Toda M, Harada E, Chelakkot-Govindalayathila AL, Roeen Z, Nagao M, D'Alessandro-Gabazza CN, Fujisawa T and Gabazza EC: Montelukast suppresses epithelial to mesenchymal transition of bronchial epithelial cells induced by eosinophils. Biochem Biophys Res Commun. 449:351–356. 2014. View Article : Google Scholar : PubMed/NCBI
15	Park JS, Jang AS, Park SW, Lee YM, Uh ST, Kim YH, Cha JY, Park SM and Park CS: Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics. Allergy Asthma Immunol Res. 2:48–54. 2010. View Article : Google Scholar : PubMed/NCBI
16	Ernst P and Ernst G: Neuropsychiatric adverse effects of montelukast in children. Eur Respir J. 50:502017. View Article : Google Scholar
17	Hossny E, Rosario N, Lee BW, Singh M, El-Ghoneimy D, Soh JY and Le Souef P: The use of inhaled corticosteroids in pediatric asthma: Update. World Allergy Organ J. 9:262016. View Article : Google Scholar : PubMed/NCBI
18	Chung KF, Caramori G and Adcock IM: Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: Present and future. Eur J Clin Pharmacol. 65:853–871. 2009. View Article : Google Scholar : PubMed/NCBI
19	van Aalderen WMC and Sprikkelman AB: Inhaled corticosteroids in childhood asthma: The story continues. Eur J Pediatr. 170:709–718. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kovesi T, Schuh S, Spier S, Bérubé D, Carr S, Watson W and McIvor RA: Achieving control of asthma in preschoolers. CMAJ. 182:E172–E183. 2010. View Article : Google Scholar : PubMed/NCBI
21	Castro-Rodriguez JA and Rodrigo GJ: Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: A systematic review with meta-analysis. Pediatrics. 123:e519–e525. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pawankar R, Holgate ST and Rosenwasser LJ: Allergy Frontiers: Therapy and PreventionSpringer; Tokyo: 2010
23	Amirav I, Newhouse MT, Minocchieri S, Castro-Rodriguez JA and Schüepp KG: Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol. 125:1206–1211. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lan WP, Wang J, Dai CL and Pan JH: Efficacy of fluticasone propionate aerosol versus budesonide suspension in treatment of recurrent wheezing caused by bronchiolitis. Zhongguo Dang Dai Er Ke Za Zhi. 18:316–319. 2016.(In Chinese). PubMed/NCBI
25	Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MCJM and Verhamme KMC: Prescription patterns, adherence and characteristics of non-adherence in children with asthma in primary care. Pediatr Allergy Immunol. 27:201–208. 2016. View Article : Google Scholar : PubMed/NCBI
26	Makhinova T, Barner JC, Richards KM and Rascati KL: Asthma Controller Medication Adherence, Risk of Exacerbation, and Use of Rescue Agents Among Texas Medicaid Patients with Persistent Asthma. J Manag Care Spec Pharm. 21:1124–1132. 2015.PubMed/NCBI
27	Wardenier NRA, Klok T, de Groot EP and Brand PLP: Height growth in children with asthma treated with guideline-recommended dosages of fluticasone and electronically assessed adherence. Arch Dis Child. 101:637–639. 2016. View Article : Google Scholar : PubMed/NCBI
28	Blais L, Kettani FZ, Forget A, Beauchesne MF, Lemière C and Ducharme FM: Assessing adherence to inhaled corticosteroids in asthma patients using an integrated measure based on primary and secondary adherence. Eur J Clin Pharmacol. 73:91–97. 2017. View Article : Google Scholar : PubMed/NCBI
29	Vasbinder EC, Goossens LMA, Rutten-van Mölken MPMH, de Winter BC, van Dijk L, Vulto AG, Blankman EI, Dahhan N, Veenstra-van Schie MT, Versteegh FG, et al: e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): A randomised controlled trial. Eur Respir J. 48:758–767. 2016. View Article : Google Scholar : PubMed/NCBI
30	Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD and O'Byrne PM: Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 166:1212–1217. 2002. View Article : Google Scholar : PubMed/NCBI
31	Stanford RH, Shah M and Chaudhari SL: Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast in children with asthma aged 4 to 11 years. Open Respir Med J. 6:37–43. 2012. View Article : Google Scholar : PubMed/NCBI